An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol.
<h4>Background</h4>Despite the proven efficacy of evidence-based healthcare interventions in reducing adverse outcomes and mortality associated with Sickle Cell Disease (SCD), a vast majority of affected individuals in Africa remain deprived of such care. Hydroxyurea (HU) utilization amo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0311900 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533182870028288 |
|---|---|
| author | Emmanuel Peprah Joyce Gyamfi John Patena Hazal Kayalioglu Tania Hameed Gbenga Ogedegbe Hyungrok Do Dike Ojji Deborah Adenikinju Tayo Ajaye Oba Maxwell Nwegbu Hezekiah Isa Grace Shedul Alayo Y Sopekan Obiageli E Nnodu |
| author_facet | Emmanuel Peprah Joyce Gyamfi John Patena Hazal Kayalioglu Tania Hameed Gbenga Ogedegbe Hyungrok Do Dike Ojji Deborah Adenikinju Tayo Ajaye Oba Maxwell Nwegbu Hezekiah Isa Grace Shedul Alayo Y Sopekan Obiageli E Nnodu |
| author_sort | Emmanuel Peprah |
| collection | DOAJ |
| description | <h4>Background</h4>Despite the proven efficacy of evidence-based healthcare interventions in reducing adverse outcomes and mortality associated with Sickle Cell Disease (SCD), a vast majority of affected individuals in Africa remain deprived of such care. Hydroxyurea (HU) utilization among SCD patients in Sub-Saharan Africa (SSA) stands at less than 1%, while in Nigeria, approximately 13% of patients benefit from HU therapy. To enhance HU utilization, targeted implementation strategies addressing provider-level barriers are imperative. Existing evidence underscores the significance of addressing barriers such as inadequate healthcare worker training to improve HU adoption. The ACCELERATE study aims to evaluate the adoption of HU among providers through the Screen, Initiate, and Maintain (SIM) intervention, facilitated by healthcare worker training, clinical reminders, and task-sharing strategies, thereby enhancing patient-level SCD management in Nigeria.<h4>Methods</h4>This study will implement the SIM intervention, encompassing patient screening, initiation of HU treatment, and maintenance of dosage, which will be implemented via the TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH TCP), derived from our team's TAsk-Strengthening Strategy for Hypertension control (TASSH) trials. Employing a sequential exploratory mixed-methods approach within the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework, this study will assess SIM adoption by providers in Nigeria. The primary outcome is the rate of SIM adoption at clinical sites at 12 months, with secondary outcomes including sustainability/maintenance of SIM intervention and implementation fidelity.<h4>Discussion</h4>This study's findings will offer crucial insights into effective SCD management strategies, leveraging existing SCD clinical networks and resources in Nigeria to enhance HU adoption among providers in a scalable and sustainable manner. Additionally, the study will inform best practices for implementing HU therapy in resource-constrained settings, benefiting healthcare providers, policymakers, and stakeholders invested in improving SCD care delivery.<h4>Trial registration</h4>NCT06318143. |
| format | Article |
| id | doaj-art-9f3a975a3324462b94ede98652da5141 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-9f3a975a3324462b94ede98652da51412025-01-17T05:31:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201e031190010.1371/journal.pone.0311900An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol.Emmanuel PeprahJoyce GyamfiJohn PatenaHazal KayaliogluTania HameedGbenga OgedegbeHyungrok DoDike OjjiDeborah AdenikinjuTayo Ajaye ObaMaxwell NwegbuHezekiah IsaGrace ShedulAlayo Y SopekanObiageli E Nnodu<h4>Background</h4>Despite the proven efficacy of evidence-based healthcare interventions in reducing adverse outcomes and mortality associated with Sickle Cell Disease (SCD), a vast majority of affected individuals in Africa remain deprived of such care. Hydroxyurea (HU) utilization among SCD patients in Sub-Saharan Africa (SSA) stands at less than 1%, while in Nigeria, approximately 13% of patients benefit from HU therapy. To enhance HU utilization, targeted implementation strategies addressing provider-level barriers are imperative. Existing evidence underscores the significance of addressing barriers such as inadequate healthcare worker training to improve HU adoption. The ACCELERATE study aims to evaluate the adoption of HU among providers through the Screen, Initiate, and Maintain (SIM) intervention, facilitated by healthcare worker training, clinical reminders, and task-sharing strategies, thereby enhancing patient-level SCD management in Nigeria.<h4>Methods</h4>This study will implement the SIM intervention, encompassing patient screening, initiation of HU treatment, and maintenance of dosage, which will be implemented via the TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH TCP), derived from our team's TAsk-Strengthening Strategy for Hypertension control (TASSH) trials. Employing a sequential exploratory mixed-methods approach within the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework, this study will assess SIM adoption by providers in Nigeria. The primary outcome is the rate of SIM adoption at clinical sites at 12 months, with secondary outcomes including sustainability/maintenance of SIM intervention and implementation fidelity.<h4>Discussion</h4>This study's findings will offer crucial insights into effective SCD management strategies, leveraging existing SCD clinical networks and resources in Nigeria to enhance HU adoption among providers in a scalable and sustainable manner. Additionally, the study will inform best practices for implementing HU therapy in resource-constrained settings, benefiting healthcare providers, policymakers, and stakeholders invested in improving SCD care delivery.<h4>Trial registration</h4>NCT06318143.https://doi.org/10.1371/journal.pone.0311900 |
| spellingShingle | Emmanuel Peprah Joyce Gyamfi John Patena Hazal Kayalioglu Tania Hameed Gbenga Ogedegbe Hyungrok Do Dike Ojji Deborah Adenikinju Tayo Ajaye Oba Maxwell Nwegbu Hezekiah Isa Grace Shedul Alayo Y Sopekan Obiageli E Nnodu An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. PLoS ONE |
| title | An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. |
| title_full | An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. |
| title_fullStr | An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. |
| title_full_unstemmed | An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. |
| title_short | An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol. |
| title_sort | implementation trial to manage sickle cell disease through increased adoption of hydroxyurea in nigeria accelerate study protocol |
| url | https://doi.org/10.1371/journal.pone.0311900 |
| work_keys_str_mv | AT emmanuelpeprah animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT joycegyamfi animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT johnpatena animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT hazalkayalioglu animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT taniahameed animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT gbengaogedegbe animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT hyungrokdo animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT dikeojji animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT deborahadenikinju animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT tayoajayeoba animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT maxwellnwegbu animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT hezekiahisa animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT graceshedul animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT alayoysopekan animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT obiageliennodu animplementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT emmanuelpeprah implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT joycegyamfi implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT johnpatena implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT hazalkayalioglu implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT taniahameed implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT gbengaogedegbe implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT hyungrokdo implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT dikeojji implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT deborahadenikinju implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT tayoajayeoba implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT maxwellnwegbu implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT hezekiahisa implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT graceshedul implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT alayoysopekan implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol AT obiageliennodu implementationtrialtomanagesicklecelldiseasethroughincreasedadoptionofhydroxyureainnigeriaacceleratestudyprotocol |